Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New antidiabetic agents imparted in recent patents

Dec. 18, 2007

A DYRK3 inhibitor shows potential for anemia therapy

Dec. 18, 2007

Savient reports positive results from GOUT 1 and 2 phase III trials of Puricase

Dec. 17, 2007

Novo Nordisk reports positive clinical results from one-year monotherapy study of liraglutide

Dec. 17, 2007

FDA approves BioMarin therapy for PKU

Dec. 14, 2007

Vivus initiates EQUATE phase III trial of Qnexa in obese patients with co-morbidities

Dec. 14, 2007

Orexigen initiates phase III trial of Contrave for obesity

Dec. 14, 2007

SIRT1 activators show therapeutic potential in animal models of type 2 diabetes

Dec. 14, 2007

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Dec. 14, 2007

Responses seen in immune thrombocytopenic purpura patients given R-788

Dec. 14, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...